Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.

Bhishamjit S Chera Siddharth H ShethShetal A PatelDan GoldinKathe E DouglasRebecca L GreenColette J ShenGaorav P GuptaDominic T MooreJuneko E Grilley OlsonJared M Weiss

Published in: Cancer (2021)

Adavosertib 100 mg (twice daily on Monday, Tuesday, and Wednesday of weeks 1, 2, 4, 5, 7, and 8), in combination with 70 Gy of intensity-modulated radiotherapy and cisplatin 30 mg/m2 , is the recommended phase 2 dose for patients with HNSCC.

Keyphrases

locally advanced
radiation induced
early stage
radiation therapy
physical activity
squamous cell carcinoma
rectal cancer
gestational age
preterm birth